Galderma agrees to acquire ZO Skin Health

{
  "signal_id": "ea1d3b95-9cc3-3459-5e20-859ef98a6d8f",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-18T15:34:34+00:00",
  "company": {
    "name": "Galderma",
    "domain": "galderma.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/galderma-agrees-to-acquire-zo-skin-health/70354755",
    "title": "Galderma agrees to acquire ZO Skin Health - ad-hoc-news.de",
    "excerpt": "Galderma announced on October 14, 2026, that it had signed an agreement to acquire 100% of ZO Skin Health from its shareholders, including funds managed by Blackstone Tactical Opportunities and the Obagi family. The transaction carries an enterprise value of USD 1.5 billion and is structured as an all-cash transaction. Galderma said it expects the deal to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and other customary closing conditions. Market context: Market report SMI . Galderma Group AG was quoted at CHF 176.05 in the finance data for October 16, 2026, with a previous close of CHF 172.15. The quote was marked closed. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Galderma stock . On October 14, 2026, Galderma announced the USD 1.5 billion ZO Skin Health agreement. On October 15, 2026, it announced phase II data for nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis. The company said the results showed meaningful improvements in itch, sleep disturbance and quality of life maintained through Week 52. Galderma said the ZO Skin Health transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to the stated conditions.",
    "product": "nemolizumab",
    "summary": "Galderma announced Phase II clinical data for nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2405051_1920_1080.webp",
    "confidence": 0.85,
    "product_data": {
      "name": "nemolizumab",
      "full_text": "nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-18T15:34:34Z",
    "effective_date": "2026-10-15",
    "article_sentence": "On October 15, 2026, it announced phase II data for nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis."
  }
}

curl https://signals.autobound.ai/v1/signals/ea1d3b95-9cc3-3459-5e20-859ef98a6d8f \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"galderma.com","limit":20}'